What is the percentage of post Endoscopic Retrograde Cholangiopancreatography (ERCP) pancreatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Post-ERCP Pancreatitis Incidence

Post-ERCP pancreatitis occurs in approximately 3.5-7.2% of all ERCP procedures, with the rate varying based on whether the procedure is diagnostic or therapeutic. 1, 2

Overall Incidence Rates

  • The most commonly cited range for post-ERCP pancreatitis is 3.5-7.2%, with the American College of Radiology reporting approximately 3.5-3.7% and prospective studies showing rates up to 7.2%. 1, 2

  • Diagnostic ERCP carries a lower risk (0.4-1.5%) compared to therapeutic ERCP (1.6-5.4%), though one large prospective study found similar rates between diagnostic and therapeutic procedures. 3, 2

  • The overall complication rate for ERCP ranges from 1.8% to 18.4%, with pancreatitis being the most common serious complication. 4

Severity Distribution

  • The vast majority (93%) of post-ERCP pancreatitis cases are mild and self-limiting, requiring only conservative treatment with IV fluids, pain management, and bowel rest. 2, 1

  • When severity is stratified: approximately 70 cases are mild, 55 moderate, and 6 severe per 1000 procedures (based on a 6.7% overall pancreatitis rate). 5

High-Risk Populations

  • Patients with sphincter of Oddi dysfunction have a 21.7% risk of post-ERCP pancreatitis, representing one of the highest-risk groups. 2

  • Those with previous ERCP-related pancreatitis face a 19-20% risk of recurrence. 2, 6

  • Patients with recurrent pancreatitis have a 16.2% risk, and those with intraductal papillary mucinous neoplasm (IPMN) have a 3-fold increased risk. 2, 6

  • Even with prophylactic pancreatic duct stenting in high-risk patients, post-ERCP pancreatitis still occurs in approximately 9.9% of cases, though severity is reduced. 7

Procedure-Specific Risk Variations

  • Endoscopic papillary balloon dilation (EPBD) without sphincterotomy carries a higher pancreatitis risk compared to sphincterotomy alone, though prolonged balloon dilation (>1 minute) reduces this risk to levels similar to sphincterotomy. 8

  • Minor papilla interventions carry a 10-15% risk of post-ERCP pancreatitis, which is substantially higher than standard ERCP. 8

  • Procedures involving precut sphincterotomy increase risk 2.25-fold, and difficult cannulation increases risk 3.49-fold. 6

Critical Context

  • The wide range in reported rates (1.8-18.4% overall complications) reflects differences in patient populations, procedural complexity, and institutional experience. 4

  • Female gender increases pancreatitis risk 1.46-2.6 fold, and guidewire manipulation in the pancreatic duct increases risk 8.2-fold. 4, 6

  • Procedure-related mortality from all ERCP complications is approximately 0.4%. 4

References

Guideline

Management of Post-ERCP Complications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Risk factors for complications after performance of ERCP.

Gastrointestinal endoscopy, 2002

Research

Post-ERCP pancreatitis.

Journal of hepato-biliary-pancreatic sciences, 2010

Guideline

Complications of Endoscopic Retrograde Cholangiopancreatography (ERCP)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Risk factors for post-ERCP pancreatitis: A systematic review and meta-analysis.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.